{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:56:48Z","timestamp":1771952208159,"version":"3.50.1"},"reference-count":129,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The eye, which is under constant exposure to environmental pathogens, has evolved various anatomic and immunological barriers critical to the protection of tissues lacking regenerative capacity, and the maintenance of a clear optic pathway essential to vision. By bypassing the ocular barriers, intravitreal (IVT) injection has become the mainstay for the delivery of drugs to treat conditions that affect the back of the eye. Both small molecules and biotherapeutics have been successfully administered intravitreally, and several drugs have been approved for the treatment of (wet) age\u2010related macular degeneration and diabetic macular edema. However, IVT injection is an invasive procedure, which requires sufficient technical expertise from the healthcare professional administering the drug. Potential side effects include bleeding, retinal tear, cataracts, infection, uveitis, loss of vision, and increased ocular pressure. Pharmaceutical companies often differ in their drug development plan, including drug administration techniques, collection of ocular tissues and fluids, ophthalmology monitoring, and overall conduct of nonclinical and clinical studies. The present effort, under the aegis of the Innovation &amp; Quality Ophthalmic Working Group, aims at understanding these differences, identifying pros and cons of the various approaches, determining the gaps in knowledge, and suggesting feasible good practices for nonclinical and early clinical IVT drug development.<\/jats:p>","DOI":"10.1111\/cts.13480","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T09:33:16Z","timestamp":1674034396000},"page":"723-741","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs"],"prefix":"10.1111","volume":"16","author":[{"given":"Ingrid M.","family":"Pruimboom\u2010Brees","sequence":"first","affiliation":[{"name":"Novartis Institutes of Biomedical Research  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-6647","authenticated-orcid":false,"given":"Swati","family":"Gupta","sequence":"additional","affiliation":[{"name":"AbbVie  Irvine California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagendra","family":"Chemuturi","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen S.","family":"Booler","sequence":"additional","affiliation":[{"name":"Novartis Institutes of Biomedical Research  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Nimz","sequence":"additional","affiliation":[{"name":"Novartis Institutes of Biomedical Research  Basel Switzerland"},{"name":"Novartis Institutes of Biomedical Research  Cambridge Massachussetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-4740","authenticated-orcid":false,"given":"Meg","family":"Ferrell\u00a0Ramos","sequence":"additional","affiliation":[{"name":"AbbVie  Irvine California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Caruso","sequence":"additional","affiliation":[{"name":"Roche  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-2863","authenticated-orcid":false,"given":"Katie F.","family":"Maass","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Bantseev","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihong","family":"Huang","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary P.","family":"Choules","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse C.","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-500X","authenticated-orcid":false,"given":"Jitendra","family":"Kanodia","sequence":"additional","affiliation":[{"name":"Xencor  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Thompson","sequence":"additional","affiliation":[{"name":"Decibel Therapeutics  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrasekar","family":"Durairaj","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220125"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl006"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-869-0_28"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2001250117"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2021.1902308"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1_7"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1_6"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1992.120"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1_10"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042307"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318770379"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.10.026"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1_11"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1_9"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1_1"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1086-1"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320978396"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0479-y"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.12974\/2309-6128.2013.01.01.1"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.07.007"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2020.106694"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21356"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0149"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312441400"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2450-1"},{"issue":"5","key":"e_1_2_13_29_1","first-page":"1","article-title":"Ophthalmic preparations","volume":"39","author":"Aldrich DS","year":"2013","journal-title":"Pharmacopeial Forum"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.204701"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4363"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00667-y"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d50cea"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6431"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21719"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/108076801753162807"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-69222-2_2"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.8.6.1"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b01191"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c01218"},{"issue":"7","key":"e_1_2_13_41_1","first-page":"1063","article-title":"Melanin concentration in normal human retinal pigment epithelium. Regional variation and age\u2010related reduction","volume":"27","author":"Schmidt SY","year":"1986","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2012.03.004"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1998.14.555"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13650"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-9233.106384"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.012"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090010125038"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1984.01040030344034"},{"issue":"3","key":"e_1_2_13_49_1","first-page":"502","article-title":"Cefazolin levels after intravitreal injection. Effects of inflammation and surgery","volume":"31","author":"Ficker L","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000265"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24480"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9728-7"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.01.003"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S19555"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3148"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9702"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.225"},{"key":"e_1_2_13_58_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM).Bioanalytical Method Validation \u2010 Guidance for Industry;2018:1\u201344."},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.12.020"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4309"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227223"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12031"},{"issue":"12","key":"e_1_2_13_63_1","first-page":"3327","article-title":"What is the biologically relevant KD for VEGF binding to ranibizumab in the eye? A comparison of in\u2010vivo and in\u2010vitro estimates","volume":"57","author":"Mazer N","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.05.025"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308264"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00849"},{"key":"e_1_2_13_67_1","unstructured":"Food and Drug Administration.S6(R1) Preclinical Safety Evaluation of Biotechnology\u2010Derived Pharmaceuticals.2012."},{"key":"e_1_2_13_68_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.2010:1\u201330."},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0120"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0063"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320976095"},{"key":"e_1_2_13_72_1","unstructured":"EMA assessment report: Eylea (Aflibercept). EMEA;2012."},{"key":"e_1_2_13_73_1","unstructured":"Shire Pharma Canada ULC.Product Monograph: Xiidra (Lifitegrast)."},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2014.961070"},{"key":"e_1_2_13_75_1","unstructured":"StrubleC.Overview of Ocular Anatomy\/Pathology and Ocular Health Evaluation for Toxicity Studies. Poster presented at: BioSafe Annual Meeting; April 2012."},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.03.013"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13707"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-015-9490-5"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.01.017"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.66"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78364-2"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6700729"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etp.2007.11.012"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0021"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1258\/002367797780600206"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0071"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0108"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1177\/01926233211047562"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02304"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.032"},{"key":"e_1_2_13_91_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0128-y"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-803620-4.00029-3"},{"key":"e_1_2_13_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1725369"},{"key":"e_1_2_13_94_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).Immunogenicity Testing of Therapeutic Protein Products\u2014Developing and Validating Assays for Anti\u2010Drug Antibody Detection.;2019:1\u201337."},{"key":"e_1_2_13_95_1","unstructured":"European Medicines Agency.Guideline on Immunogenicity Assessment of Therapeutic Proteins;2017:1\u201324."},{"key":"e_1_2_13_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(91)32280-2"},{"key":"e_1_2_13_97_1","unstructured":"U.S Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).Immunogenicity Assessment for Therapeutic Protein Products;2014:1\u201339."},{"key":"e_1_2_13_98_1","unstructured":"TurnerO SaravananC GaoY et al.Immunohistochemical characterization of ocular inflammationassociated with intravitreal biotherapeutics. Poster Presented at: STP 36th Annual Symposium Musculoskeletal System;2017."},{"key":"e_1_2_13_99_1","unstructured":"KumarV AbbasAK AsterJC.Robbins & Cotran Pathologic Basis of Disease;2020."},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314526475"},{"key":"e_1_2_13_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.12.030"},{"key":"e_1_2_13_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.03.003"},{"key":"e_1_2_13_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.06.017"},{"key":"e_1_2_13_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100040"},{"key":"e_1_2_13_105_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-21809"},{"key":"e_1_2_13_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2569-8"},{"key":"e_1_2_13_107_1","doi-asserted-by":"publisher","DOI":"10.1177\/2515841420903929"},{"issue":"6","key":"e_1_2_13_108_1","first-page":"58","article-title":"A novel biomarker for stargardt disease?","volume":"150","author":"Sherman J","year":"2013","journal-title":"Rev Optometry"},{"key":"e_1_2_13_109_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3946531"},{"key":"e_1_2_13_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200410000-00002"},{"key":"e_1_2_13_111_1","doi-asserted-by":"publisher","DOI":"10.1159\/000486145"},{"key":"e_1_2_13_112_1","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202203.0164.v1"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.11254\/jscvo.34.11"},{"key":"e_1_2_13_114_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.082974"},{"key":"e_1_2_13_115_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713688108999452"},{"key":"e_1_2_13_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78364-2_2"},{"key":"e_1_2_13_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-018-1037-5"},{"key":"e_1_2_13_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0163-1"},{"key":"e_1_2_13_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0721-9"},{"key":"e_1_2_13_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-469235-0.50025-7"},{"key":"e_1_2_13_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-5224.2008.00619.x"},{"key":"e_1_2_13_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12665"},{"key":"e_1_2_13_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-164-6_1"},{"key":"e_1_2_13_124_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2001.62.853"},{"key":"e_1_2_13_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12642"},{"key":"e_1_2_13_126_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00280"},{"key":"e_1_2_13_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09713-0"},{"key":"e_1_2_13_128_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.52.1290"},{"key":"e_1_2_13_129_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.263178"},{"key":"e_1_2_13_130_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320948851"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T07:57:00Z","timestamp":1692431820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/cts.13480"],"URL":"https:\/\/doi.org\/10.1111\/cts.13480","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"2022-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}